Intelligent Bio Solutions (INBS) Non-Current Deffered Revenue (2021 - 2022)

Intelligent Bio Solutions (INBS) recorded quarterly Non-Current Deffered Revenue of $1.6 million in Q4 2022, down 39.73% quarter-over-quarter from $2.6 million in Q3 2022, and up 35.39% on a YoY basis from $1.2 million in Q4 2021.

Intelligent Bio Solutions (INBS) Non-Current Deffered Revenue (2021 - 2022) Analysis & Trends

Intelligent Bio Solutions' Non-Current Deffered Revenue history runs 2 years deep, the most recent figure standing at $1.6 million for Q4 2022.

  • In Q4 2022, Non-Current Deffered Revenue rose 35.39% year-over-year to $1.6 million; the TTM figure through Dec 2022 stood at $1.6 million (up 35.39% YoY), while the FY2022 annual figure was $1.1 million, down 65.29% from the prior year.
  • Non-Current Deffered Revenue was $1.6 million for Q4 2022 at Intelligent Bio Solutions, down from $2.6 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $3.1 million in Q2 2021 to a low of $1.1 million in Q2 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Abbott Laboratories 154.42 Bn 147.76 Bn 6.27 Bn -
2 Stryker 118.12 Bn 115.25 Bn 3.81 Bn -
3 Medtronic 101.72 Bn 93.55 Bn 5.76 Bn -
4 Boston Scientific 67.19 Bn 65.98 Bn 3.61 Bn -
5 Edwards Lifesciences 50.69 Bn 47.02 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 512.79 Mn
7 Dexcom 28.09 Bn 26.97 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.08 Bn 26.02 Bn 1.98 Bn -
9 Steris 19.80 Bn 19.37 Bn 697.10 Mn -
10 Intelligent Bio Solutions 12.67 Mn 11.47 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2022 1.56 Mn
Sep 30, 2022 2.59 Mn
Jun 30, 2022 1.09 Mn
Mar 31, 2022 1.19 Mn
Dec 31, 2021 1.15 Mn
Sep 30, 2021 2.74 Mn
Jun 30, 2021 3.15 Mn